Pfizer Inc. (NYSE:PFE) Shares Purchased by Banque Pictet & Cie SA

Banque Pictet & Cie SA increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,108 shares of the biopharmaceutical company’s stock after acquiring an additional 1,318 shares during the period. Banque Pictet & Cie SA’s holdings in Pfizer were worth $401,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PFE. Wells Trecaso Financial Group LLC increased its holdings in Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock valued at $416,000 after buying an additional 350 shares during the last quarter. Washington Trust Advisors Inc. grew its holdings in shares of Pfizer by 0.7% during the third quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock valued at $1,424,000 after purchasing an additional 360 shares during the last quarter. PSI Advisors LLC grew its holdings in shares of Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 385 shares during the last quarter. Western Pacific Wealth Management LP grew its holdings in shares of Pfizer by 10.5% during the third quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 386 shares during the last quarter. Finally, Waddell & Associates LLC grew its holdings in shares of Pfizer by 1.6% during the third quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company’s stock valued at $723,000 after purchasing an additional 388 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.50 on Friday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The stock has a fifty day moving average of $26.28 and a 200-day moving average of $27.58. The company has a market capitalization of $144.48 billion, a PE ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the firm earned $0.10 EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.75%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 121.99%.

Insider Activity

In other news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Guggenheim reiterated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.